🚀 Gate Square “Gate Fun Token Challenge” is Live!
Create tokens, engage, and earn — including trading fee rebates, graduation bonuses, and a $1,000 prize pool!
Join Now 👉 https://www.gate.com/campaigns/3145
💡 How to Participate:
1️⃣ Create Tokens: One-click token launch in [Square - Post]. Promote, grow your community, and earn rewards.
2️⃣ Engage: Post, like, comment, and share in token community to earn!
📦 Rewards Overview:
Creator Graduation Bonus: 50 GT
Trading Fee Rebate: The more trades, the more you earn
Token Creator Pool: Up to $50 USDT per user + $5 USDT for the first 50 launche
Fuhong Hanlin: Grants Alvogen Korea exclusive license for Hans.
Jin10 Data reported on April 25 that Fuhong Hanlin announced that the company has entered into a licensing protocol with Alvogen Korea Co., Ltd., granting it exclusive rights to commercialize Hanshuang (Srilumab injection) in South Korea. Under the protocol, Alvogen Korea will pay an upfront payment of $5 million, with regulatory milestone payments not exceeding $9.5 million, commercial sales milestone payments not exceeding $97.5 million, and tiered royalties calculated based on annual net sales ranging from 18% to 25%. The licensing protocol will take effect from the date of signing and will initially last until the 10th anniversary of the first commercial sale of the licensed product.